# A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

> **NCT05951816** · PHASE1 · UNKNOWN · sponsor: **University of Tennessee Graduate School of Medicine** · enrollment: 35 (estimated)

## Conditions studied

- Systemic Amyloidosis

## Interventions

- **DRUG:** 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.
- **DRUG:** 99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.

## Key facts

- **NCT ID:** NCT05951816
- **Lead sponsor:** University of Tennessee Graduate School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2023-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05951816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05951816, "A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05951816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*